Tempest Reports Year End 2025 Financial Results and Provides Business Update
Tempest Therapeutics announced its 2025 year-end financial results alongside significant corporate updates including the strategic acquisition of next-generation dual-targeting CAR-T assets from Factor Bioscience. The company highlighted positive interim Phase 1/2a clinical data for TPST-2003 in relapsed/refractory multiple myeloma, demonstrating a…